Astral Limited
Financial trend (75/100) does the heavy lifting; valuation (1/100) is the drag.
ExpensiveOvervaluedStocksWizard rates Astral Limited a Sell, scoring 43/100 on our blended model. At ₹1,476.3 it trades above our blended DCF and relative-multiples fair value of ₹738.15, about 50% downside to that estimate — we read it as overvalued by 50%. On 77.0x trailing earnings it sits pricier than the Industrials median of about 29.0x. The price is about 15% below its 52-week high of ₹1,746.3 and 17% above the low of ₹1,265.88. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 5/9. The average analyst target of ₹1,763.62 implies about 19% upside across 29 analysts. It clears 7 of 13 investability checks, with durability 60, valuation 1 and momentum 46 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹590.52.
Analyst views
1-year price
EOD · 2026-07-2952-week range
-15.46% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Sell43Piotroski F-score 5/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: 13.8%
- Pass: Low debt (D/E < 0.5): 0.06x
- Pass: Positive free cash flow
- Pass: Revenue growth > 10%: 24%
- Pass: Earnings growing: 19%
- Fail: Net margin ≥ 10%: 8.2%
- Pass: Current ratio > 1.5: 1.76
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Fail: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 16.24
- Fail: Piotroski ≥ 7: 5/9
Quarterly results
Annual financials
Shareholding
- Promoter54.3%
- Institutions28.8%
- Public & other16.9%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Financially solid — Altman Z 16.24.
Opportunities
- Earnings growing (19% YoY).
- Revenue growing (24% YoY).
Bear case
Weaknesses
- Price below its 200-day moving average (downtrend).
Threats
- Rich valuation versus sector peers.
- Trades ~50% above our estimated fair value.
About Astral Limited
Astral Limited engages in the manufacture and marketing of pipes and fittings, water tanks, and adhesives and sealants in India and internationally. It operates in two segments, Plumbing, and Paints and Adhesives. It offers plumbing pipes and fittings, sewerage and drainage pipes and fittings, agriculture pipes and fittings, cable protection system, industrial piping system, fire protection system, urban infrastructure, ancillary products, and column pipe; and roto moulding,
Astral Limited — frequently asked questions
Is Astral Limited a buy, hold or sell?
StocksWizard currently rates Astral Limited (ASTRAL) a Sell, based on a blended score of 43/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Astral Limited's fair value?
Our blended DCF and relative-valuation model estimates Astral Limited's fair value at about ₹738.15, versus a current price of ₹1,476.3 — roughly 50% downside. On that basis the stock looks overvalued by 50%.
Is Astral Limited financially healthy?
Astral Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 5/9.
How has Astral Limited's share price performed?
Astral Limited is down 3% over three months, and last traded at ₹1,476.3. Past performance doesn't predict future returns.
More in Industrials
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.